Vulvovaginal symptoms and sexual function: Complementary therapies

Background
Grading of Clinical Practice Recommendations
Clinical Practice Recommendations and Practice Points
Summary of Evidence - Methodology
Summary of Evidence - Introduction
Summary of Evidence - Vasomotor symptoms
- Vasomotor symptoms: Pharmacological interventions
- Vasomotor symptoms: Hormonal interventions
- Vasomotor symptoms: Psychological and physical interventions
- Vasomotor symptoms: Complementary therapies
Summary of Evidence - Sleep disturbance
- Sleep disturbance: Pharmacological interventions
- Sleep disturbance: Hormonal interventions
- Sleep disturbance: Psychological and physical interventions
- Sleep disturbance: Complementary therapies
Summary of Evidence - Vulvovaginal symptoms and sexual function
- Vulvovaginal symptoms and sexual function: Pharmacological interventions
- Vulvovaginal symptoms and sexual function: Hormonal interventions
- Vulvovaginal symptoms and sexual function: Psychological and physical interventions
- Vulvovaginal symptoms and sexual function: Complementary therapies
Summary of Evidence - Depression and anxiety
- Depression and anxiety: Pharmacological interventions
- Depression and anxiety: Hormonal interventions
- Depression and anxiety: Psychological and physical interventions
- Depression and anxiety: Complementary therapies
Summary of Evidence - Mood and emotional wellbeing
- Mood and emotional wellbeing: Pharmacological interventions
- Mood and emotional wellbeing: Hormonal interventions
- Mood and emotional wellbeing: Psychological and physical interventions
Summary of Evidence - Mental health
- Mental health: Pharmacological interventions
- Mental health: Psychological and physical interventions
Summary of Evidence - Global quality of life
- Global quality of life: Pharmacological interventions
- Global quality of life: Hormonal interventions
- Global quality of life: Psychological and physical interventions
- Global quality of life: Complementary therapies
Summary of Evidence - Breast cancer recurrence
Strengths and Weaknesses of the Evidence
Unanswered Questions Regarding Treatments of Interest
International Guidelines
Ongoing and Additional Trials of Interest
Drug Contraindications and Side Effects
Evidence Matrix
References
Acknowledgements
Additional Information
Appendix 1: Grading Methodology
Appendix 2: Evidence Summaries
Appendix 3: Recommendation Grading Forms

Phytoestrogens

Six RCTs (with a high risk of bias) identified in a Systematic review (with a moderate risk of bias) in menopausal women found that soy isoflavones had an uncertain effect on vaginal dryness and dyspareunia compared to placebo.⁸⁸ [ES64]

About Cancer Australia

Cancer Australia was established by the Australian Government in 2006 to benefit all Australians affected by cancer, and their families and carers. Cancer Australia aims to reduce the impact of cancer, address disparities and improve outcomes for people affected by cancer by leading and coordinating national, evidence-based interventions across the continuum of care.

If you would like an interpreter to help you understand any information on this website, please call TIS National on 131 450 and ask them to call Cancer Australia on 02 9357 9400. Our business hours are 9am to 5pm, Monday to Friday.

Freecall 1800 624 973
+61 2 9357 9400

Locked Bag 3, Strawberry Hills
NSW 2012

Vulvovaginal symptoms and sexual function: Complementary therapies